basic and diluted 146,296 79,709 123,634 78,672
Biodesix, Inc.
Reconciliation of Net Loss to Adjusted EBITDA (unaudited)
(in thousands)
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------- ---------------------
2024 2023 2024 2023
-------- ---------- -------- ----------
Net loss $(10,258) $ (10,949) $(34,680) $ (43,007)
Interest
expense 2,041 2,386 6,506 7,207
Depreciation
and
amortization 1,492 782 4,324 2,351
Share-based
compensation
expense 1,515 954 5,373 4,292
Loss on
extinguishment
of liabilities -- -- 248 --
COVID-19
Revenue -- -- -- (13)
COVID-19 Direct
costs and
expenses -- -- -- 1
Change in fair
value of
warrant
liability,
net -- 1,393 -- 1,332
Other expense
(income), net (374) (2) 77 (4)
------- --------- ------- ---------
Adjusted EBITDA $ (5,584) $ (5,436) $(18,152) $ (27,841)
======= ========= ======= =========
(END) Dow Jones Newswires
November 01, 2024 06:00 ET (10:00 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。